SI2118128T1 - Fuzijski proteini, ki obsegajo tumorska zavrnitvena antigena NY-ESO-1 in LAGE-1 - Google Patents

Fuzijski proteini, ki obsegajo tumorska zavrnitvena antigena NY-ESO-1 in LAGE-1

Info

Publication number
SI2118128T1
SI2118128T1 SI200830870T SI200830870T SI2118128T1 SI 2118128 T1 SI2118128 T1 SI 2118128T1 SI 200830870 T SI200830870 T SI 200830870T SI 200830870 T SI200830870 T SI 200830870T SI 2118128 T1 SI2118128 T1 SI 2118128T1
Authority
SI
Slovenia
Prior art keywords
lage
eso
fusion proteins
tumor rejection
rejection antigens
Prior art date
Application number
SI200830870T
Other languages
English (en)
Slovenian (sl)
Inventor
Normand Blais
Martine Boyer
Vincent Brichard
Jamila Louahed
Denis Martin
Remi M. Palmantier
Clement Rioux
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0700759A external-priority patent/GB0700759D0/en
Priority claimed from GB0709707A external-priority patent/GB0709707D0/en
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of SI2118128T1 publication Critical patent/SI2118128T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SI200830870T 2007-01-15 2008-01-11 Fuzijski proteini, ki obsegajo tumorska zavrnitvena antigena NY-ESO-1 in LAGE-1 SI2118128T1 (sl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0700759A GB0700759D0 (en) 2007-01-15 2007-01-15 Novel fusion protein
US91484807P 2007-04-30 2007-04-30
US91492507P 2007-04-30 2007-04-30
GB0709707A GB0709707D0 (en) 2007-05-21 2007-05-21 Novel fusion protein
PCT/US2008/050879 WO2008089074A2 (en) 2007-01-15 2008-01-11 Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1
EP08727588A EP2118128B1 (en) 2007-01-15 2008-01-11 Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1

Publications (1)

Publication Number Publication Date
SI2118128T1 true SI2118128T1 (sl) 2013-02-28

Family

ID=41111108

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200830870T SI2118128T1 (sl) 2007-01-15 2008-01-11 Fuzijski proteini, ki obsegajo tumorska zavrnitvena antigena NY-ESO-1 in LAGE-1

Country Status (15)

Country Link
EP (1) EP2118128B1 (enExample)
JP (1) JP2010532656A (enExample)
KR (1) KR20090122426A (enExample)
BR (1) BRPI0806501A2 (enExample)
CA (1) CA2674458A1 (enExample)
DK (1) DK2118128T3 (enExample)
EA (1) EA016818B1 (enExample)
ES (1) ES2398492T3 (enExample)
HR (1) HRP20130022T1 (enExample)
MX (1) MX2009007572A (enExample)
PE (1) PE20081687A1 (enExample)
PL (1) PL2118128T3 (enExample)
SI (1) SI2118128T1 (enExample)
TW (1) TW200902049A (enExample)
WO (1) WO2008089074A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008308474A (ja) * 2007-06-18 2008-12-25 Nitto Denko Corp 抗原ペプチド製剤の調製方法
AU2010225125A1 (en) 2009-03-17 2011-10-20 Glaxosmithkline Biologicals S.A. Improved detection of gene expression
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
JP6041314B2 (ja) * 2011-08-31 2016-12-07 国立大学法人三重大学 がん治療用ワクチン製剤
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2014207708A2 (en) 2013-06-28 2014-12-31 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
US20160367651A1 (en) 2013-10-01 2016-12-22 Mie University T cell inducing vaccine containing an interepitope sequence that promotes antigen presentation
JP2018505152A (ja) 2014-12-23 2018-02-22 アン ブリンブル マーガレット アミノ酸複合体及びペプチド複合体ならびにそれらの使用
CA3014515A1 (en) 2016-02-26 2017-08-31 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
IL283279B2 (en) * 2018-11-23 2025-08-01 Strike Pharma Ab Bi-specific conjugates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06205672A (ja) * 1992-03-19 1994-07-26 Nippon Zeon Co Ltd 日本脳炎ウイルス及びｂ型肝炎ウイルスの表面抗原タンパク質の抗原部位を持つキメラタンパク質の製造法、およびそれに用いる組み換えバキュロウイルス
US6686147B1 (en) * 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
DE60144516D1 (de) * 2000-03-30 2011-06-09 Dendreon Corp Zusammensetzungen und verfahren für eine auf dendritischen zellen basierende immuntherapie
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
CA2551644C (en) * 2003-12-24 2014-03-04 Cerus Corporation Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of usethereof
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
MX2007005256A (es) * 2004-11-16 2008-03-11 Crucell Holland Bv Vacunas multivalentes que comprenden vectores virales recombinantes.
JP2009538286A (ja) * 2006-05-26 2009-11-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 癌に対するワクチン接種
CN101668770B (zh) * 2007-01-15 2013-06-12 葛兰素史密丝克莱恩生物有限公司 疫苗

Also Published As

Publication number Publication date
WO2008089074A2 (en) 2008-07-24
EP2118128A2 (en) 2009-11-18
WO2008089074A3 (en) 2008-12-31
BRPI0806501A2 (pt) 2014-04-22
DK2118128T3 (da) 2013-02-18
EP2118128B1 (en) 2012-11-07
MX2009007572A (es) 2009-10-13
JP2010532656A (ja) 2010-10-14
WO2008089074A9 (en) 2012-07-12
EA016818B1 (ru) 2012-07-30
HRP20130022T1 (hr) 2013-02-28
EA200900738A1 (ru) 2010-02-26
KR20090122426A (ko) 2009-11-30
ES2398492T3 (es) 2013-03-19
PE20081687A1 (es) 2008-12-25
TW200902049A (en) 2009-01-16
CA2674458A1 (en) 2008-07-24
PL2118128T3 (pl) 2013-03-29

Similar Documents

Publication Publication Date Title
PL2118128T3 (pl) Białka fuzyjne zawierające antygeny odrzucenia nowotworu NY-ESO-1 i LAGE-1
ZA201002160B (en) Human gm-csf antigen binding proteins
EP2069401A4 (en) MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE
ZA201003759B (en) Antibodies against human nkg2d and uses thereof
EP2211888A4 (en) ALBUM INFUSION PROTEINS
IL232008A (en) Protein isolate heterodimer alpha-4-in-cell-7-specific antigen-binding and various aspects thereof
IL217121A0 (en) Antimicrobial fusion proteins and uses thereof
IL200373A0 (en) Antibodies against erbb3 and uses thereof
IL200808A0 (en) Soluble il-17ra/rc fusion proteins and related methods
IL202128A0 (en) Immunoglobulin fusion proteins
IL201034A0 (en) Novel human anti-r7v antibodies and uses thereof
SI2144924T1 (sl) Cepivo s fuzijskimi beljakovinami
IL201386A0 (en) Tem8 peptides and vaccines comprising the same
HUS1800034I1 (hu) Anti-FGF23 ellenanyag és anti-FGF23 ellenanyagot tartalmazó gyógyászati készítmény
PT2457928T (pt) Anticorpo monoclonal humano específico de tumores
IL203429A0 (en) Immunogenic polypeptides and monoclonal antibodies
EP2797629A4 (en) AGLYCOSYLATED HUMAN ANTIBODY AND FUSION PROTEIN AND USES THEREOF
IL209869A0 (en) Iqgap3 epitope peptides and vaccines containing the same
ZA200901680B (en) Recombinant human interferon-like proteins
IL206334A0 (en) Sarp-i fusion proteins and their use
PT2118128E (pt) Proteínas de fusão compreendendo os antigénios de rejeição tumoral ny-eso-1 e lage-1
GB0700759D0 (en) Novel fusion protein
PL380011A1 (pl) Nowe szkieletowe preparaty białkowe, sposób ich otrzymywania oraz zastosowania
GB0709707D0 (en) Novel fusion protein
GB0503190D0 (en) Human antibodies